Study of Everolimus in de Novo Renal Transplant Recipients

NATerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
End Stage Renal Failure With Renal Transplant
Interventions
DRUG

Everolimus

"On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended."

Trial Locations (4)

35500-227

Hospital São João de Deus/Fundação Geraldo Corrêa, Divinópolis

35160-158

Hospital Márcio Cunha/Fundação São Francisco Xavier, Ipatinga

36036-330

Fundação IMEPEN, Juiz de Fora

39400-103

Hospital do Rim de MOntes Claros/Irmandade Nossa Senhora das Mercês, Montes Claros

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Helady Pinheiro, MD, PhD

OTHER

NCT01609673 - Study of Everolimus in de Novo Renal Transplant Recipients | Biotech Hunter | Biotech Hunter